Cytokine hemoadsorption with CytoSorb
Cardiac arrest
Cytokine hemoadsorption
Extracorporeal blood purification
Hemoperfusion
Inflammation
Post-cardiac arrest syndrome
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
23 01 2023
23 01 2023
Historique:
received:
21
11
2022
accepted:
14
01
2023
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
26
1
2023
Statut:
epublish
Résumé
Hemoadsorption (HA) might mitigate the systemic inflammatory response associated with post-cardiac arrest syndrome (PCAS) and improve outcomes. Here, we investigated the feasibility, safety and efficacy of HA with CytoSorb In this pilot randomized controlled trial, we included patients admitted to our intensive care unit following CA and likely to develop PCAS: required norepinephrine (> 0.2 µg/kg/min), and/or had serum lactate > 6 mmol/l and/or a time-to-return of spontaneous circulation (ROSC) > 25 min. Those requiring ECMO or renal replacement therapy were excluded. Eligible patients were randomly allocated to either receive standard of care (SOC) or SOC plus HA. Hemoadsorption was performed as stand-alone therapy for 24 h, using CytoSorb We enrolled 21 patients, of whom 16 (76%) had out-of-hospital CA. Median (IQR) time-to-ROSC was 30 (20, 45) minutes. Ten were assigned to the HA group and 11 to the SOC group. Hemoadsorption was initiated in all patients allocated to the HA group within 18 (11, 23) h of ICU admission and conducted for a median duration of 21 (14, 24) h. The intervention was well tolerated except for a trend for a higher rate of aPTT elevation (5 (50%) vs 2 (18%) p = 0.18) and mild (100-150 G/L) thrombocytopenia at day 1 (5 (50%) vs 2 (18%) p = 0.18). Interleukin (IL)-6 plasma levels at randomization were low (< 100 pg/mL) in 10 (48%) patients and elevated (> 1000 pg/mL) in 6 (29%). The median relative reduction in IL-6 at 48 h was 75% (60, 94) in the HA group versus 5% (- 47, 70) in the SOC group (p = 0.06). In CA survivors at risk of PCAS, HA was feasible, safe and was associated with a nonsignificant reduction in cytokine plasma levels. Future trials are needed to further define the role of HA after CA. Those studies should include cytokine assessment to enrich the study population. NCT03523039, registered 14 May 2018.
Sections du résumé
BACKGROUND
Hemoadsorption (HA) might mitigate the systemic inflammatory response associated with post-cardiac arrest syndrome (PCAS) and improve outcomes. Here, we investigated the feasibility, safety and efficacy of HA with CytoSorb
METHODS
In this pilot randomized controlled trial, we included patients admitted to our intensive care unit following CA and likely to develop PCAS: required norepinephrine (> 0.2 µg/kg/min), and/or had serum lactate > 6 mmol/l and/or a time-to-return of spontaneous circulation (ROSC) > 25 min. Those requiring ECMO or renal replacement therapy were excluded. Eligible patients were randomly allocated to either receive standard of care (SOC) or SOC plus HA. Hemoadsorption was performed as stand-alone therapy for 24 h, using CytoSorb
RESULTS
We enrolled 21 patients, of whom 16 (76%) had out-of-hospital CA. Median (IQR) time-to-ROSC was 30 (20, 45) minutes. Ten were assigned to the HA group and 11 to the SOC group. Hemoadsorption was initiated in all patients allocated to the HA group within 18 (11, 23) h of ICU admission and conducted for a median duration of 21 (14, 24) h. The intervention was well tolerated except for a trend for a higher rate of aPTT elevation (5 (50%) vs 2 (18%) p = 0.18) and mild (100-150 G/L) thrombocytopenia at day 1 (5 (50%) vs 2 (18%) p = 0.18). Interleukin (IL)-6 plasma levels at randomization were low (< 100 pg/mL) in 10 (48%) patients and elevated (> 1000 pg/mL) in 6 (29%). The median relative reduction in IL-6 at 48 h was 75% (60, 94) in the HA group versus 5% (- 47, 70) in the SOC group (p = 0.06).
CONCLUSIONS
In CA survivors at risk of PCAS, HA was feasible, safe and was associated with a nonsignificant reduction in cytokine plasma levels. Future trials are needed to further define the role of HA after CA. Those studies should include cytokine assessment to enrich the study population.
TRIAL REGISTRATION
NCT03523039, registered 14 May 2018.
Identifiants
pubmed: 36691082
doi: 10.1186/s13054-023-04323-x
pii: 10.1186/s13054-023-04323-x
pmc: PMC9869834
doi:
Substances chimiques
Cytokines
0
Interleukin-6
0
Banques de données
ClinicalTrials.gov
['NCT03523039']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Informations de copyright
© 2023. The Author(s).
Références
JAMA. 2010 Jun 2;303(21):2165-71
pubmed: 20516417
J Intensive Care Med. 2020 Mar;35(3):219-224
pubmed: 30526209
Crit Care Med. 2015 Aug;43(8):1622-9
pubmed: 25853591
Intensive Care Med. 2013 Nov;39(11):1972-80
pubmed: 23942856
Circulation. 2021 May 11;143(19):1841-1851
pubmed: 33745292
Resuscitation. 2017 Dec;121:179-186
pubmed: 28947390
Ann Intensive Care. 2011 Nov 03;1(1):45
pubmed: 22053891
Resuscitation. 2003 Sep;58(3):297-308
pubmed: 12969608
Crit Care Med. 2002 Sep;30(9):1987-94
pubmed: 12352031
Resuscitation. 2016 Jun;103:117-124
pubmed: 26826561
Resuscitation. 2022 Apr;173:169-178
pubmed: 35143902
J Cardiol. 2020 Sep;76(3):295-302
pubmed: 32305260
Resuscitation. 2021 Feb;159:54-59
pubmed: 33385467
Resuscitation. 2016 Jan;98:1-8
pubmed: 26525271
Crit Care. 2021 Dec 17;25(1):434
pubmed: 34920723
Intensive Care Med. 2021 Apr;47(4):369-421
pubmed: 33765189
Crit Care. 2013 Feb 04;17(1):204
pubmed: 23394211
Sci Rep. 2021 May 18;11(1):10493
pubmed: 34006946
Resuscitation. 2021 Apr;161:61-79
pubmed: 33773833
PLoS One. 2020 Nov 3;15(11):e0241709
pubmed: 33141843
Intensive Care Med. 2013 Sep;39(9):1535-46
pubmed: 23740278
Blood Purif. 2021;50(6):750-757
pubmed: 33440377
Resuscitation. 2014 Nov;85(11):1480-7
pubmed: 25150183
Resuscitation. 2009 Feb;80(2):189-93
pubmed: 19010583
Front Cardiovasc Med. 2022 May 31;9:899583
pubmed: 35711345
J Am Coll Cardiol. 2005 Aug 2;46(3):432-7
pubmed: 16053954